IN THE UNITED STATES PATENT AND TRADEMARK OFFI

In re Application of:

Shashoua, Victor E.

Serial No.:

Filed: APR 2 6 2002 Entitled:

09/715,763

November 17, 2000

COMPOSITIONS AND METHODS FOR COUNTERACTING EFFECTS OF REACTIVE OXYGEN SPECIES AND FREE RADICALS

Art Unit: 1653

Examiner: Mitra, R.

Attorney Docket No.: CMX-001.1 US

U.S. Patent and Trademark Office **Box Sequence** P.O Box 2327

RECEIVED

MAY 0 3 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith are: [X] a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; [X] a sequence listing in written and computer readable form; [X] a preliminary amendment and a statement under 37 CFR § 1.821 and 1.825; and [X] a return receipt post card, for filing in the above-identified patent application.

PAYMENT OF FEES

Arlington, VA 22202

[]	A check in the amount of \$	in payment of the fee for submission of an information disclosure
	statement transmitted herewith.	

The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR [X]§§ 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0268. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Leon R. Yankwidh; Registration No. 30,237

Thomas R. Berka, Ph.D.; Registration No. 39,606

Attorney(s) for Applicants

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as "Express Mail Post Office to Addressee" Service under 37 CFR § 1.10, postage prepaid, Express Mailing Label No. EL378886201US, in an envelope addressed to the U. S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date indicated below.



Notice to Comply

Application No.

09/715763 Examiner

Rita Mitra, Ph. D.

Shashoua

Art Unit

1653

Applicar

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Z)	attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
\boxtimes	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY